The rights issue has been subscribed for over SEK 4 million, but the board has set the lowest limit for completing the issue at SEK 5.5 million. The management is discussing with some investors which could lead to the company reaching the level of SEK 5.5 million.

"We are grateful to everyone who subscribed to the rights issue so that we can continue with our projects that can change the lives of those suffering from osteoarthritis, but also create great value for the shareholders, as today's share price in no way reflects the values found in the company. Therefore, we choose to extend the subscription period and work hard to get the last capital in," says Hanne Evenbratt, CEO of Cline Scientific AB.

The complete issue memorandum and registration forms are published on the Company's website www.clinescientific.com and Nordic Issuing's website www.nordic-issuing.se.

The company is listed on the Nasdaq First North Growth Market. Redeye AB is Cline Scientific's Certified Adviser.

This information is information that Cline Scientific is required to disclose pursuant to the EU Market Abuse Regulation. The information was submitted for publication by the contact person set out above, at 1:14pm CEST on 18 July 2023.

For more information, please contact:

Hanne Evenbratt, CEO
Email: hanne.evenbratt@clinescientific.com
Phone: +46 703-585088